Relay Therapeutics, Inc. $RLAY Shares Sold by Private Capital Advisors Inc.

Private Capital Advisors Inc. trimmed its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 87.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,648 shares of the company’s stock after selling 388,091 shares during the quarter. Private Capital Advisors Inc.’s holdings in Relay Therapeutics were worth $280,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Commodore Capital LP acquired a new stake in shares of Relay Therapeutics in the 2nd quarter valued at about $46,191,000. Woodline Partners LP increased its holdings in Relay Therapeutics by 448.4% in the first quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock valued at $3,979,000 after buying an additional 1,241,657 shares during the last quarter. Bellevue Group AG increased its holdings in Relay Therapeutics by 11.6% in the second quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock valued at $28,479,000 after buying an additional 853,578 shares during the last quarter. Norges Bank bought a new position in Relay Therapeutics during the 2nd quarter worth approximately $2,892,000. Finally, Bank of America Corp DE lifted its holdings in Relay Therapeutics by 138.1% during the 2nd quarter. Bank of America Corp DE now owns 1,320,130 shares of the company’s stock worth $4,568,000 after buying an additional 765,702 shares during the last quarter. Institutional investors own 96.98% of the company’s stock.

Wall Street Analysts Forecast Growth

RLAY has been the subject of a number of research analyst reports. Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target for the company in a report on Monday, January 26th. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Relay Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $16.57.

Relay Therapeutics Stock Performance

RLAY stock opened at $9.22 on Thursday. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.54. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -5.27 and a beta of 1.59. The stock’s fifty day moving average is $8.31 and its two-hundred day moving average is $6.65.

Insider Activity

In related news, CFO Thomas Catinazzo sold 13,820 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $105,308.40. Following the sale, the chief financial officer directly owned 250,996 shares in the company, valued at $1,912,589.52. This trade represents a 5.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Donald A. Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $143,979.90. Following the sale, the insider directly owned 422,733 shares in the company, valued at $3,221,225.46. The trade was a 4.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 93,302 shares of company stock valued at $724,355. 4.87% of the stock is owned by company insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.